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BACH-1 expression. Similar antisense
strategies directed against both endoge-
nous mir-k12-11 and mir-155 could help
identify which candidate targets are sub-
jects for more in depth study.
To better understand KSHV-associated
pathogenesis, it will be important to test
the most promising candidate miRNA tar-
gets in other relevant models, such as cul-
tured primary endothelial cells as well as
in vivo models. KSHV is particularly adept
at ‘‘pirating’’ host protein coding genes
into its genome; thus, it makes sense
that KSHV would also tap into an existing
host miRNA regulatory pathway. From
a viral perspective, the ability to target
many genes involved in an existing regu-
latory network may provide more ‘‘evolu-
tionary bang for your buck.’’ Indeed, it is
likely that this strategy is not unique to
KSHV, as other viral miRNAs display vari-
ous degrees of seed identity with host
miRNAs (Gottwein et al., 2007; Skalsky
et al., 2007).
On the whole, these two studies sug-
gest that mir-k12-11 and mir-155 share
a set of common mRNA targets that
form a part of a regulatory network impor-
tant for B cell function, cell-cycle regula-
tion, and apoptosis. All of these pathways
could play an important role in the lym-
phomagenesis associated with misex-
pression of mir-155 or KSHV infection
(Figure 2). This is an exciting time in the
world of viral miRNAs, where the field is
poised for an avalanche of miRNA tar-
get discoveries. The next challenge will
be to integrate these findings into a better
understanding of viral life cycle and
pathogenesis.
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Vertebrates rely on antimicrobial peptides as a front-line defense against invading pathogens. Certain
cationic antimicrobial peptides, such as human a-defensins, have traditionally been thought to destroy
invading microbes by disrupting their lipid membranes. In this issue of Cell Host & Microbe, Smith and
Nemerow reveal that a-defensins can inactivate adenoviruses, which lack lipid membranes, through direct
binding of the defensin to the virus’s naked protein shell.Vertebrates employ an impressive arsenal
of molecular weapons to defend them-
selves against invading microbes. One
defense mechanism involves the local
release of noxious chemicals, such as
reactive oxygen intermediates, that are
capable of directly destroying microbial
structures. Obviously, the use of such
broadly reactive chemicals must be tightly
controlled to avoid catastrophic damage
to host tissues. Control over these sys-
tems typically involves a variety of signal-ing proteins, for example, the toll-like
receptors, which are specifically engaged
by broadly conserved pathogen-associ-
ated molecular patterns (PAMPs). Fortu-
nately, the vertebrateantimicrobial arsenal
also includes a wide variety of bacterioci-
dal and virucidal peptides that are rela-
tively harmless to host cells. Because of
their low toxicity to hostcells, antimicrobial
peptides can be produced constitutively
at relatively high concentrations in micro-
environments such as the outer layers ofCell Host & Micthe skin, the crypts of the small intestines,
and the phagosomes of neutrophils,
which typically serve as immunological
first responders at sites of infection.
A group of antimicrobial peptides aptly
named defensins were first discovered
more than 40 years ago as a bacteriocidal
component abundant in rabbit neutro-
phils. Defensins and defensin-like pep-
tides have since been identified in a broad
range of organisms ranging from fungi to
insects to humans (reviewed in Lehrer,robe 3, January 2008 ª2008 Elsevier Inc. 3
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Previews2007). This broad distribution suggests
that defensin-like peptides originated
prior to the emergence of the last com-
mon ancestor of fungi and animals
roughly a billion years ago.
Humans express two classes of defen-
sins, a- and b-, that are distinguished
based on the pattern of intramolecular di-
sulfide bonds that stabilize their primarily
b-stranded fold. Defensins are amphi-
pathic and cationic at neutral pH, leading
to the initial hypothesis that their cognate
PAMPs might be various negatively
charged headgroups that are characteris-
tic of some types of bacterial membranes.
Defensins are, in fact, membrane active
and have been shown to disrupt bacterial
membranes in vitro (Lehrer et al., 1989).
However, it is now clear that defensins
can exert a variety of other effects against
a broad spectrum of pathogenic mi-
crobes, including various membrane-en-
veloped viruses and, surprisingly, several
nonenveloped viruses, including adenovi-
rus type 5, adeno-associated virus type 2,
and papillomaviruses (Bastian and Scha-
fer, 2001; Buck et al., 2006; Gropp et al.,
1999; Virella-Lowell et al., 2000). It has
been suggested that defensins can act
against enveloped viruses, such as HIV-1,
through various mechanisms, including
membrane disruption, direct blocking of
virus-receptor interactions, and interfer-
ence (perhaps intracellularly) with cellular
signaling pathways (Chang et al., 2005;
and reviewed in Yang et al., 2007). In con-
trast, it has remained unclear how defen-
sins antagonize the infectious entry of
nonenveloped viruses.
In this issue of Cell Host & Microbe,
Smith and Nemerow (2008) elucidate the
general mechanism by which human
neutrophil peptide-1 (HNP-1) and human
defensin-5 (HD-5) (both a-defensins) an-
tagonize the infectivity of adenovirus
types 5 and 35. Their work shows that the
a-defensins bind directly to the nonenvel-
oped adenoviral capsid. Defensin binding
was shown to interfere with the develop-
ment of conformational changes thought
to be required for exposure of capsid
motifs that facilitate escape of the viral
genome from endosomal compartments.
The work clearly supports the idea that
a-defensins act primarily by stabilizing4 Cell Host & Microbe 3, January 2008 ª200the environment around the icosahedral
vertices of the capsid, thereby blocking
the development of capsid conformational
changes required for infectious penetra-
tion of the host cell membranes. Support-
ing experiments clearly rule out ancillary
effects from other proposed antiviral
mechanisms, such as competition of the
a-defensins against primary virus-recep-
tor interactions. The fact that virions repuri-
fied after a-defensin pretreatment remain
noninfectious argues against the possibil-
ity that the defensins act by globally alter-
ing cellular signaling functions. However,
the possibility that the defensins might be
released from the virion during infectious
entry and exert local effects on the cell is
very difficult to entirely rule out.
It’s puzzling that adenoviruses should
preserve high-affinity defensin-binding
motifs in their capsidstructures. Moreover,
the fact that a-defensins arrest papilloma-
viruses at a similar point in their infectious
entry process suggests that a similar Achil-
les’ heel may also be present in an unre-
lated family of nonenveloped viruses with
a markedly different capsid geometry and
infectious entry pathway. One possibility
is that the a-defensins target a PAMP-like
virion motif that is so important for produc-
tive infection that it has been indepen-
dently created by convergent evolution in
multiple, unrelated nonenveloped virus
families and preserved even in the face of
apparent negative selective pressure
from a-defensins.
Another conceivable explanation is that
some virus types are under positive selec-
tive pressure to refrain from infecting cells
that are bathed in a-defensins. In addition
to their constitutive expression in some
specialized microenvironments, the ex-
tracellular release of many defensin types,
including HNP-1 and HD-5, can increase
dramatically in response to inflammatory
stimuli. Furthermore, HNPs 1–3 and other
defensin types can serve directly as
immunological signaling molecules (re-
viewed in Yang et al., 2007). In general,
inflammatory environments are effective
sites for the priming of adaptive immune
responses. Thus, susceptibility to defen-
sins might serve to prohibit individual
virions from infecting microenvironments
especially conducive to elicitation of8 Elsevier Inc.adaptive immune responses capable of
systemic eradication of an infection.
Such a selection mechanism seems
especially plausible for DNA viruses, such
as adenoviruses and papillomaviruses,
that utilize host the cell’s DNA polymerase
machinery for high-fidelity replication of
their genomes. A prediction of the hy-
pothesis that some virus types voluntarily
maintain susceptibility to defensins would
be that it might be relatively easy to select
for defensin-resistant viral variants in vitro.
If they could be produced, defensin-resis-
tant variants would, paradoxically, be
expected to be less fit in immune-com-
petent hosts.
Regardless of the teleological roots of
this viral Achilles’ heel, the clear potential
prize for understanding its fundamental
mechanism in more detail could be the
eventual development of broad-spectrum
antiviral agents. Although a-defensins
already represent such agents, they are
relatively long peptides (several dozen
amino acids), and their manufacture may
be complicated by the need to form the
proper arrangement of internal disulfide
bonds. Thus, small-molecule inhibitors
targeting antimicrobial peptide-sensitive
sites on viral surfaces would likely be
needed for practical applications.
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